HCG Manavata Cancer Centre completes world-first in robotic-assisted nipple sparing mastectomy

Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers

The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2

Zydus receives approval from COFEPRIS of Mexico to market ‘Bhava’ to treat various cancers

Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality

Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer

Imfinzi also recommended for patients with mismatch repair deficient disease

HCG acquires 51% stake in Mahatma Gandhi Cancer Hospital and Research Institute, Vizag

Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza

Imfinzi improved event-free survival and overall survival for bladder cancer

First immunotherapy regimen before and after surgery to extend survival in bladder cancer

Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy